Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Breast Neoplasms 33Neoplasms 31Melanoma 24Neoplasm Metastasis 22Leukemia, Myeloid, Acute 21Colorectal Neoplasms 18Prostatic Neoplasms 17Multiple Myeloma 17Lung Neoplasms 17Ovarian Neoplasms 14Myelodysplastic Syndromes 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 12Lymphoma, Non-Hodgkin 12Carcinoma, Renal Cell 11Uterine Cervical Neoplasms 10Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Glioblastoma 10Brain Neoplasms 10Carcinoma, Hepatocellular 9Stomach Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma 7Hodgkin Disease 7Head and Neck Neoplasms 7Glioma 7

Interventions

belantamab mafodotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Plasmablastic Lymphoma × 90 days × Clear all
NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡